FCCC LOGO Faculty Publications
Berlin JD , Propert KJ , Trump D , Wilding G , Hudes G , Glick J , Burch P , Keller A , Loehrer P
5-fluorouracil and leucovorin therapy in patients with hormone refractory prostate cancer - An Eastern Cooperative Oncology Group phase II study (E1889)
American Journal of Clinical Oncology-Cancer Clinical Trials. 1998 Apr;21(2) :171-176
PMID: ISI:000072929100016   
Back to previous list
Abstract
This report is a multi-institutional phase II study designed to obtain the response rate, survival, and toxicity profile for patients having hormone-refractory prostate cancer. Patients who had bidimensionally measurable prostate carcinoma in first or second remission after previous hormonal therapy but no history of chemotherapy were eligible. Patients were treated with leucovorin, 20 mg/m(2) intravenously, followed by 5- fluorouracil (5-FU), 425 mg/m(2) intravenously daily for 5 days, with cycles repeated every 28 days. Of 38 eligible patients, 3 (7.9%) had partial responses to therapy and 20 (52.6%) had stable disease. Median survival was 11.6 months for all 38 patients and median time to progression was 4.4 months. Most of the serious side effects were gastrointestinal or hematologic and overall, 23 of 38 patients (60.5%) experienced at least one grade 3 or 4 treatment related toxicity of any type, as measured by the National Cancer Institute common toxicity criteria. Five patients (13.2%) withdrew from the study because of adverse reactions from chemotherapy. We conclude that treatment of hormone-refractory prostate cancer patients with 5-FU and leucovorin chemotherapy produced few responses at the cost of significant side effects. Further investigation of this combination is not warranted in this setting.
Notes
Times Cited: 5 English Article ZF749 AMER J CLIN ONCOL-CANC CLIN T